The US Food & Drug Administration’s approval of AstraZeneca PLC and Daiichi Sankyo Co., Ltd.’s antibody-drug conjugate Enhertu for HER2-low metastatic breast cancer is the culmination of months of anticipation and a key milestone in the firms’ goal to expand Enhertu’s reach, but AstraZeneca noted during its recent second quarter earnings report that the success the drug is seeing so far does not yet reflect use in the new indication.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?